Cryoglobulinemia future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
Created page with "__NOTOC__ {{Cryoglobulinemia}} {{CMG}}; '''Associate Editor-In-Chief:''' {{CZ}} ==Overview== == Future or Investigational Therapies == * In patients with acute, severe dis..." |
Kiran Singh (talk | contribs) |
||
| Line 13: | Line 13: | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Hematology]] | [[Category:Hematology]] | ||
[[Category:Rheumatology]] | [[Category:Rheumatology]] | ||
[[Category:Blood tests]] | [[Category:Blood tests]] | ||
{{WikiDoc Help Menu}} | |||
{{WikiDoc Sources}} | |||
Revision as of 13:30, 17 June 2015
|
Cryoglobulinemia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Cryoglobulinemia future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Cryoglobulinemia future or investigational therapies |
|
Cryoglobulinemia future or investigational therapies in the news |
|
Blogs on Cryoglobulinemia future or investigational therapies |
|
Risk calculators and risk factors for Cryoglobulinemia future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]
Overview
Future or Investigational Therapies
- In patients with acute, severe disease, plasmapheresis has been used in conjunction with high dose steroids and cytoxan.
- Uncontrolled studies demonstrated a reduction in creatinine in up to 87% of patients.